Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Genvoya

Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16

HOS-133994 · Präparat HOS-097520

Elvitegravir: AUC: ↔ Cmin: ↔ Cmax: ↔ ORAL CONTRACEPTIVES Drospirenone/Ethinyloestradiol Interaction not studied with Plasma concentrations of (3 mg/0.02 mg single dose)/ Genvoya. drospirenone may be increased Cobicistat (150 mg once daily) when co-administered with Expected cobicistat-containing products. Drospirenone: Clinical monitoring is recommended AUC: ↑ due to the potential for hyperkalaemia. Norgestimate Norelgestromin: (0.180/0.215/0.250 mg once daily)/ AUC: ↔ Caution should be exercised when Ethinyloestradiol (0.025 mg once Cmin: ↔ co-administering Genvoya and a daily)/ Emtricitabine/Tenofovir Cmax: ↔ hormonal contraceptive. The alafenamide (200/25 mg once hormonal contraceptive should daily)6 Norgestrel: contain at least 30 µg AUC: ↔ ethinyloestradiol and contain Cmin: ↔ drospirenone or norgestimate as the Cmax: ↔ progestogen or patients should use an alternative reliable method of Ethinyloestradiol: contraception (see sections 4.4 and AUC: ↔ 4.6). Cmin: ↔ Cmax: ↔ The long-term effects of substantial increases in progestogen exposure are unknown. Norgestimate (0.180/0.215 mg Norgestimate: once daily)/ Ethinyloestradiol AUC: ↑ 126% (0.025 mg once daily)/ Elvitegravir Cmin: ↑ 167% (150 mg once daily)/ Cobicistat Cmax: ↑ 108% (150 mg once daily)4 Ethinyloestradiol: AUC: ↓ 25% Cmin: ↓ 44% Cmax: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) norgestimate (HOS-110544) norelgestromin (HOS-110295) drospirenone (HOS-116422) norgestrel (HOS-090613)